## Zhiwei Hu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2405528/publications.pdf

Version: 2024-02-01

279798 377865 1,883 40 23 34 h-index citations g-index papers 41 41 41 1966 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Platelet TLR4-ERK5 Axis Facilitates NET-Mediated Capturing of Circulating Tumor Cells and Distant Metastasis after Surgical Stress. Cancer Research, 2021, 81, 2373-2385.	0.9	72
2	Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 1271-1283.	3.7	162
3	Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy., 2021,, 193-212.		1
4	Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers, 2021, 13, 5333.	3.7	29
5	Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer. Molecules, 2020, 25, 4964.	3.8	22
6	Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Scientific Reports, 2020, 10, 2815.	3.3	73
7	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. Cancer Immunology Research, 2018, 6, 671-684.	3.4	29
8	Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio) Tj ETQq0 0	0 rgBT /O	verJock 10 Tf
9	Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases. Antibodies, 2018, 7, 8.	2.5	8
10	Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy. Angiogenesis, 2017, 20, 85-96.	7.2	37
11	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clinical Cancer Research, 2017, 23, 489-502.	7.0	46
12	The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. Journal of Thoracic Disease, 2017, 9, 4226-4229.	1.4	10
13	Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. Oncotarget, 2017, 8, 1481-1494.	1.8	26
14	Fluorescent nanodiamonds and their use in biomedical research. , 2016, , .		3
15	Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON., 2015, 3,.		0
16	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	2.8	239
17	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis, 2015, 36, S184-S202.	2.8	41
18	Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases. Journal of Analytical & Bioanalytical Techniques, 2014, S1, .	0.6	15

#	Article	IF	CITATIONS
19	Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer. Journal of Immune Based Therapies, Vaccines and Antimicrobials, 2013, 02, 1-8.	0.2	5
20	Dual-Targeting of Tumor Cells and Tumor Neovasculature by Tissue Factor- Targeted Photodynamic Therapy. Journal of Analytical & Bioanalytical Techniques, 2012, 03, .	0.6	1
21	Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. British Journal of Cancer, 2011, 104, 1401-1409.	6.4	48
22	Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. Breast Cancer Research and Treatment, 2011, 126, 589-600.	2.5	26
23	Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy. Current Cancer Drug Targets, 2011, 11, 1069-1081.	1.6	33
24	Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunology, 2010, 11, 49.	2.2	26
25	Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivoin mice. BMC Cancer, 2010, 10, 235.	2.6	56
26	hl-con1, a factor VII-lgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal of Cancer, 2010, 103, 812-819.	6.4	26
27	The Immunoconjugate "lcon―Targets Aberrantly Expressed Endothelial Tissue Factor Causing Regression of Endometriosis. American Journal of Pathology, 2010, 176, 1050-1056.	3.8	72
28	Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. , 2009, 50, 3890.		18
29	Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent and–independent mechanisms. Blood, 2007, 110, 133-141.	1.4	270
30	Targeting Tissue Factor for Immunotherapy of Choroidal Neovascularization by Intravitreal Delivery of Factor VII-Fc Chimeric Antibody. Ocular Immunology and Inflammation, 2007, 15, 3-10.	1.8	43
31	Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Therapy, 2007, 14, 346-353.	4.6	37
32	Tumor Cell-Associated Tissue Factor Supports Metastatic Potential through Both NK Cell-Dependent and -Independent Mechanisms Blood, 2006, 108, 66-66.	1.4	1
33	Interplay between Tumor Cell-Associated and Circulating Coagulation Factors in Establishing Metastatic Potential Blood, 2005, 106, 686-686.	1.4	1
34	Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2679-2684.	7.1	86
35	Antigen-Driven Stimulation of B-Lymphocytes In Vitro. , 2002, 178, 113-119.		0
36	Retroviral-mediated transmission of a mouse VL30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6269-6273.	7.1	40

## Zhiwei Hu

#	Article	lF	CITATION
37	Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12180-12185.	7.1	106
38	Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9221-9225.	7.1	67
39	Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8161-8166.	7.1	96
40	Factor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and Leukemia., 0, , .		5